Status:
COMPLETED
Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty
Lead Sponsor:
OrthoCarolina Research Institute, Inc.
Conditions:
Knee Pain Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to quantify the total blood serum levels of bupivacaine in OrthoPAT® collected blood 2 hours and 5 hours postoperatively. Hypothesis: Filtered blood from the OrthoPAT® au...
Detailed Description
Total joint arthroplasty (TJA) is a commonly performed surgical procedure that can result in considerable postoperative pain which can limit social and functional recovery and a return to quality of l...
Eligibility Criteria
Inclusion
- Patients undergoing primary total joint arthroplasty with use of periarticular bupivicaine and liposomal bupivicaine and OrthoPAT® auto reinfusion system.
- At least 18 years of age.
Exclusion
- Allergy to bupivacaine.
- Allergy to epinephrine.
- Patients that are not presenting for a primary TJA
- Patients who are having a TJA without OrthoPAT® auto reinfusion system.
- Patients under age 18.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2017
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT02276040
Start Date
October 1 2014
End Date
June 30 2017
Last Update
November 30 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
OrthoCarolina, PA
Charlotte, North Carolina, United States, 28207
2
Novant Health Charlotte Orthopedic Hospital
Charlotte, North Carolina, United States, 28209
3
OrthoCarolina Research Institute, OrthoCarolina, P.A.
Charlotte, North Carolina, United States, 28209
4
OrthoCarolina, PA
Charlotte, North Carolina, United States, 28209